Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05747443

Multilevel Interventions to Increase Adherence to Lung Cancer Screening

Screening for lung cancer has the potential for a profound public health benefit. Repeat annual screening is necessary for early detection of lung cancer. The investigators will test two interventions which include patient education and reminders to improve adherence to lung cancer screening.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

50 year–78 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kaiser Permanente

Seattle, Washington, 98101, United States

About this study

Screening for lung cancer has the potential for a profound public health benefit.

Successful population-based screening requires continuous monitoring to adherence repeat screening in high risk adults to achieve similar results. Repeat annual screening is necessary for early detection of lung cancer. Baseline or first LDCT scans detect prevalent lung cancer, when subsequent screening detects new nodules. However, adherence to screening is low, ranging at 28-38% from centers nationally.

The investigators developed two novel, patient-centered interventions to address patient education and offering reminders for on-time screening. To address these goals, the specific aims are to: 1) Compare effectiveness of two multilevel interventions relative to usual care in improving (a) rates of adherence to lung cancer screening, (b) patient-centered outcomes; and (c) clinic outcomes; and 2) Determine the patient-, clinician-, and system-level factors that influence changes in adherence to inform lung cancer screening programs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • KPWA members
  • Aged 50-78 years
  • Have a negative screening LDCT scan
  • Speak English or Spanish
  • Meet US Preventive Services Task Force guidelines

Exclusion criteria

  • Patients who were previously diagnosed with lung cancer,
  • Patients who have a positive scan,
  • Patients who have an indicator for interpreter services, except for Spanish

Treatment and study plan

Stepped Reminders

Other

Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.

Patient Education

Other

The Patient Voices Video is an educational video about lung cancer screening.

Primary outcomes

  1. Rate of repeat annual lung cancer screening

    Time frame: 9-15 months after index LDCT

    Electronic health records will be searched for screening low dose CT (LDCT).

Secondary outcomes

  1. Knowledge of lung cancer screening

    Time frame: 8 weeks after index LDCT

    Knowledge of lung cancer screening eligibility, time to return and cost on patient reported outcomes survey.

  2. Attitudes and beliefs

    Time frame: 8 weeks after index LDCT

    The Lung Cancer Screening Health Belief Scale measures self-efficacy for lung cancer screening. The self-efficacy for lung cancer screening scale ranges from 9-36, with higher scores indicating lower self-efficacy.

Sponsors and collaborators

Lead sponsor

Kaiser Permanente

Other

Collaborators

  • Fred Hutchinson Cancer Center
  • Hackensack Meridian Health

Registry information

Acronym: Larch

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Feb 28, 2023
Registry last updated
Dec 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.